Drug Overview
Duaklir Pressair ([aclidinium + formoterol]; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily fixed-dose combination of the long-acting beta 2 agonist formoterol and the long-acting muscarinic antagonist aclidinium. It received EU approval for use in chronic obstructive pulmonary disease (COPD) in November 2014. AstraZeneca l.that it plans to file for US and Japanese regulatory approval of Duaklir Pressair for COPD in 2018.
While Duaklir Pressair demonstrated statistically significant improvements in trough forced expiratory volume in one second compared to its individual components and placebo in its Phase III program in COPD, the author forecasts the drug to have significantly lower uptake compared to the most promising LABA/LAMA combinations, Utibron ([indacaterol + glycopyrrolate]; Sunovion/Novartis/Pfizer/Sosei) and Stiolto Respimat ([olodaterol + tiotropium]; Boehringer Ingelheim). Duaklir Pressair’s anticipated late arrival to the US market will significantly restrict its commercial potential, despite AstraZeneca’s experience in the respiratory market. Duaklir Pressair is forecast to face significant competition from triple-combination therapies, further impacting its market share.
Duaklir Pressair ([aclidinium + formoterol]; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily fixed-dose combination of the long-acting beta 2 agonist formoterol and the long-acting muscarinic antagonist aclidinium. It received EU approval for use in chronic obstructive pulmonary disease (COPD) in November 2014. AstraZeneca l.that it plans to file for US and Japanese regulatory approval of Duaklir Pressair for COPD in 2018.
While Duaklir Pressair demonstrated statistically significant improvements in trough forced expiratory volume in one second compared to its individual components and placebo in its Phase III program in COPD, the author forecasts the drug to have significantly lower uptake compared to the most promising LABA/LAMA combinations, Utibron ([indacaterol + glycopyrrolate]; Sunovion/Novartis/Pfizer/Sosei) and Stiolto Respimat ([olodaterol + tiotropium]; Boehringer Ingelheim). Duaklir Pressair’s anticipated late arrival to the US market will significantly restrict its commercial potential, despite AstraZeneca’s experience in the respiratory market. Duaklir Pressair is forecast to face significant competition from triple-combination therapies, further impacting its market share.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
